RxDoctor Payments Data

Gustavo Dubois, MD

Pulmonary Disease · Birmingham, ALNPI 1427013580

Payments from drug & device makers

$2,290in general payments, 2019–2025

Across 109 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$511
  • Insmed, Inc.$157
  • Harmony Biosciences LLC$105
  • Sanofi$97
  • Regeneron Healthcare Solutions, Inc.$83
  • plus $299 from 9 others

What the payments were for

  • Food & beverage$2,19096%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,290 in reported general payments places this provider in the 40th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$29,209
Medicare patients
112
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter323$212,448
XolairOmalizumab12$40,459
Spiriva RespimatTiotropium Bromide27$14,642
Breo ElliptaFluticasone/Vilanterol31$13,678
Spiriva HandihalerTiotropium Bromide20$10,630
DuleraMometasone/Formoterol17$10,307
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,066
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$7,300
Wixela InhubFluticasone Propion/Salmeterol15$4,557
Albuterol Sulfate HfaAlbuterol Sulfate113$3,549
Montelukast Sodium232$2,929
Modafinil16$1,356
Zolpidem Tartrate ErZolpidem Tartrate13$1,002
Fluticasone Propionate32$603
Trazodone Hcl45$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,038$226,126354 claims
Boehringer IngelheimSpiriva Respimat$14$14,64227 claims
AstraZenecaBreztri Aerosphere$511$10,06616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →